ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: treat-to-target

Tumor Necrosis Factor Inhibitors May Slow the Progression of Spondyloarthritis

Lara C. Pullen, PhD  |  November 16, 2021

Recent research indicates tumor necrosis factor inhibitors may slow disease progression in the spine of patients with axial spondyloarthritis.

Filed under:Axial SpondyloarthritisConditions Tagged with:axial spondyloarthritis (SpA)TNFtumor necrosis factor (TNF) inhibitorstumor necrosis factor inhibitor (TNFi)

Gout Research at a Glance: ‘My picks for the top research in gout presented at ACR Convergence 2021’

Lisa Stamp, MBChB, PhD  |  November 10, 2021

Dr. Lisa Stamp helps filter the noise to get to the key insights from the research abstracts on gout presented at ACR Convergence 2021.

Filed under:ACR ConvergenceConditionsGout and Crystalline ArthritisMeeting Reports Tagged with:ACR Convergence – GoutACR Convergence 2021ACR Convergence 2021 – Gout

TNF Inhibitors & Pregnancy: How Well Does the Treatment Guidance Work?

Michele B. Kaufman, PharmD, BCGP  |  October 21, 2021

Ghalandari et al. sought to validate the guidance outlined by EULAR for the use of anti-rheumatic drugs during pregnancy, finding that following its guidance for tumor necrosis factor inhibitors led to no or low concentrations of these agents in cord blood.

Filed under:Drug UpdatesEULAR/OtherMeeting Reports Tagged with:EULARpregnancypregnant womenTNF inhibitorsTNFiWomen

The Dual-Target Strategy in Rheumatoid Arthritis: Put Patients First

Ricardo J.O. Ferreira, RN, PhD; Leonard H. Calabrese, DO; & José A.P. Da Silva, MD, PhD  |  October 13, 2021

The impressive progress of medical knowledge and technology reinforces our trust in the scientific methodology that made it all possible. However, that progress also creates risks related to the primary goal of medical care: to serve our patients’ interests and enjoyment of life in the best possible way. In this article we present our views…

Filed under:ConditionsPatient PerspectiveRheumatoid ArthritisSpeak Out Rheum Tagged with:Disease Activity Score (DAS)patient centerednessshared decision makingSpeak Out RheumatologyTreat-to-Target

Psoriatic Arthritis Treatment Update

Mary Choy, PharmD, BCGP, FASHP  |  October 13, 2021

About 30% of patients with psoriasis have psoriatic arthritis (PsA), a complex, multi-faceted, chronic, inflammatory musculoskeletal and skin disease for which the treatment has changed considerably over the past few years.1 Biosimilars and other new drugs have become a therapeutic turning point for many patients suffering from rheumatic illnesses, including PsA. The treatment of PsA…

Filed under:Clinical Criteria/GuidelinesConditionsDrug UpdatesPsoriatic Arthritis Tagged with:PsA Resource Centerpsoriatic arthritis

Treatment Factors to Consider in Patients with JIA

Jason Liebowitz, MD, FACR  |  July 18, 2021

Weighing treatment options and adjusting them to meet the needs of patients with JIA is a complicated process. Experts discussed factors influencing treatment options, optimizing treatment doses and possibilities for treatment withdrawal for these patients.

Filed under:ConditionsMeeting Reports Tagged with:JIAjuvenile idiopathic arthritis (JIA)Pediatric RheumatologyPediatric Rheumatology SymposiumPRSYMTreatment

More Equal Care: The Power of Diversity, Equity & Inclusion in Rheumatology

Jason Liebowitz, MD, FACR  |  July 17, 2021

Diversity, equity and inclusion have implications for pediatric patient care and the rheumatology workforce.

Filed under:Meeting ReportsProfessional Topics Tagged with:Diversityhealth disparitiesinclusionPediatric Rheumatology SymposiumPRSYMrace

Early & Long-Term Remission of Spondyloarthritis

Jason Liebowitz, MD, FACR  |  July 16, 2021

Filip Van den Bosch, MD, described his strategies for caring for patients with SpA and the possibility of achieving disease inactivity.

Filed under:Axial SpondyloarthritisConditionsEULAR/OtherMeeting Reports Tagged with:EULARpatient carespondyloarthritis

MDGRPHaCS / shutterstock.com

The ACR Releases an Updated Treatment Guideline for Rheumatoid Arthritis

Ruth Jessen Hickman, MD  |  June 14, 2021

In early June, the ACR released an updated guideline on the management of rheumatoid arthritis, which includes new recommendations for specific high-risk groups.1 The guideline includes 44 recommendations—seven of which are strong and 37 conditional. It underscores the role of methotrexate as a cornerstone therapy and emphasizes minimizing glucocorticoids, when possible. Guideline Development Process At…

Filed under:Clinical Criteria/GuidelinesConditionsRheumatoid Arthritis Tagged with:RA Resource Center

Gut Feeling: A Comprehensive Look at the Pathogenesis, Management & Treatment of Inflammatory Bowel Disease

Jason Liebowitz, MD, FACR  |  May 24, 2021

Patients with autoimmune diseases, such as spondyloarthritis, are at risk of developing inflammatory bowel disease. Here are considerations for its management and treatment.

Filed under:ConditionsMeeting Reports Tagged with:ACR State-of-the-Art Clinical SymposiumIBDinflammatory bowel disease (IBD)

  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 18
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences